Condition: Gonorrhea Male · Chlamydia (Male) · Syphilis Male · Sponsor: University of Washington
Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-recommended periodic presumptive treatment (PPT) or doxycycline post-exposure prophylaxis (doxyPEP), compared to standard syndromic treatment, with 18 months of follow-up and rigorous culture-based and molecular analysis of antimicrobial resistance in Neisseria gonorrhoeae. This work will provide critical data needed to inform guidelines and improve STI control among MSM in sub-Saharan Africa and other resource-limited settings, including modelled estimates of the health and economic impact of scaling up these two interventions on STI control among MSM and their partners in Kenya.
This description comes directly from the study's public registry record.
Susan M Graham, MD, PhD, MPH · +1-206-351-0414 · grahamsm@uw.edu
Eduard J Sanders, MD, PhD, MPH · +254-723-593762 · esanders@auruminstitute.org
Always discuss trial participation with your own doctor first.
| Anza Mapema Clinic | Kisumu, Kenya | Recruiting |
| University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa | Mombasa, Kenya | Recruiting |
| TRANSFORM Clinic | Nairobi, Kenya | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06468462